Emergent BioSolutions | EBS - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 956.47M 105.02M 2026-06
Akebia Therapeutics USD 155.55M 7.1M 2026-06
ALKERMES USD 511.53M 159.98M 2026-06
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Amarin USD 143.56M 12.5M 2026-06
ANI Pharmaceuticals USD 360.21M 49.04M 2026-06
BioMarin Pharmaceutical USD 874M 1.35B 2026-06
Coherus Biosciences USD 82.92M 32.32M 2026-06
Emergent BioSolutions USD 111.7M 23.9M 2023-12
Exelixis USD 281.45M 55.3M 2026-06
Glaxosmithkline GBP 3.44B 146M 2026-03
Heron Therapeutics USD 20.72M 5.4M 2026-06
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
Ironwood Pharmaceuticals USD 220.47M 5.01M 2026-03
Lexicon Pharmaceuticals USD 38.09M 3.76M 2026-03
Lonza CHF 719M 188M 2025-12
Merck USD 6.85B 1.52B 2026-06
Moderna USD 1.72B 185M 2026-06
Myriad Genetics USD 115.2M 9.2M 2026-06
Nektar Therapeutics USD 149.58M 134.46M 2026-03
Neurocrine Biosciences USD 332.4M 65.9M 2026-06
Pacira USD 205.88M 61.57M 2026-06
Pfizer USD 976M 727M 2026-06
PTC Therapeutics USD 1.05B 215.9M 2026-06
Sanofi EUR 6.35B 806M 2026-06
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
United Therapeutics USD 1.8B 523.5M 2026-06
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12